シェーグレン症候群(Sjogren’s Syndrome)：世界の治験レビュー（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Sjogren’s Syndrome 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sjogren’s Syndrome to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sjogren’s Syndrome to Immunology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sjogren’s Syndrome 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Sjogren’s Syndrome Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Sjogren’s Syndrome 32
Mar 24, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial 32
Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 32
Mar 17, 2015: Aldeyra Therapeutics Opens Enrollment in Sjogren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol 32
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 33
Clinical Trial Profiles 34
Clinical Trial Overview of Top Companies 34
Novartis AG 34
Clinical Trial Overview of Novartis AG 34
F. Hoffmann-La Roche Ltd. 35
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35
Volution Immuno Pharmaceuticals (VIP) SA 36
Clinical Trial Overview of Volution Immuno Pharmaceuticals (VIP) SA 36
Takeda Pharmaceutical Company Limited 37
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 37
Parion Sciences, Inc. 38
Clinical Trial Overview of Parion Sciences, Inc. 38
Bristol-Myers Squibb Company 39
Clinical Trial Overview of Bristol-Myers Squibb Company 39
AstraZeneca PLC 40
Clinical Trial Overview of AstraZeneca PLC 40
Amgen Inc. 41
Clinical Trial Overview of Amgen Inc. 41
Akorn, Inc. 42
Clinical Trial Overview of Akorn, Inc. 42
Actavis plc 43
Clinical Trial Overview of Actavis plc 43
Clinical Trial Overview of Top Institutes / Government 44
National Institute of Dental and Craniofacial Research 44
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 44
University Medical Center Groningen 45
Clinical Trial Overview of University Medical Center Groningen 45
Assistance Publique – Hopitaux de Paris 46
Clinical Trial Overview of Assistance Publique – Hopitaux de Paris 46
Chiba University 47
Clinical Trial Overview of Chiba University 47
Kanazawa Medical University 48
Clinical Trial Overview of Kanazawa Medical University 48
The National Institute of Allergy and Infectious Diseases 49
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 49
University of Sao Paulo 50
Clinical Trial Overview of University of Sao Paulo 50
Centre Hospitalier Regional Universitaire de Montpellier 51
Clinical Trial Overview of Centre Hospitalier Regional Universitaire de Montpellier 51
Centre Hospitalier Universitaire de Bordeaux 52
Clinical Trial Overview of Centre Hospitalier Universitaire de Bordeaux 52
Chang Gung Memorial Foundation 53
Clinical Trial Overview of Chang Gung Memorial Foundation 53
Five Key Clinical Profiles 54
Appendix 76
Abbreviations 76
Definitions 76
Research Methodology 77
Secondary Research 77
About GlobalData 78
Contact Us 78
Disclaimer 78
Source 78